Study details
Enrolling now
Imaging Immune Activation in HIV by PET-MR
CellSight Technologies, Inc.
NCT IDNCT03684655ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 7.1 years
Ages
18+
Locations
1 site in CA
What this study is about
This trial is testing a treatment called [18F]F-AraG to see where it goes in the body when you have HIV. Participants will receive one injection of this drug and then undergo imaging scans using PET-MR technology. The goal is to understand how the drug distributes within the body, particularly in individuals with HIV.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Immune, Infectious